Clinical oncology department, Faculty of medicine, Ain Shams University, Cairo, Egypt.
Crit Rev Oncol Hematol. 2015 Apr;94(1):45-54. doi: 10.1016/j.critrevonc.2014.11.009. Epub 2014 Dec 18.
Thyroid cancer is the most common endocrine malignancy, representing 1% of all human malignancies; its incidence has been escalating worldwide during the last decades. In recent years important molecular pathways contributing to tumor progression and worse survival rates have been identified in iodine-refractory differentiated thyroid carcinoma (DTC) with the consequent development of molecular therapeutics to target these specific oncogenic pathways. For example, a positive correlation has been found between expression of vascular endothelial growth factor (VEGF) and a more aggressive phenotype of DTC. This has led to the widespread adoption of VEGF-targeted therapeutics in the preclinical and clinical settings. In this review we will provide an overview of the different aspects of the use of VEGF-pathway-oriented treatments in iodine-refractory DTC with particular focus on future prospects.
甲状腺癌是最常见的内分泌恶性肿瘤，占人类恶性肿瘤的 1%；在过去几十年中，其发病率在全球范围内不断上升。近年来，在碘难治性分化型甲状腺癌（DTC）中发现了一些重要的促进肿瘤进展和降低生存率的分子途径，从而开发了针对这些特定致癌途径的分子治疗方法。例如，血管内皮生长因子（VEGF）的表达与 DTC 更具侵袭性的表型之间存在正相关。这导致 VEGF 靶向治疗在临床前和临床环境中的广泛应用。在这篇综述中，我们将概述碘难治性 DTC 中 VEGF 通路定向治疗的不同方面，并特别关注未来的前景。
